Company Valuation: Cardiol Therapeutics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 142 43.96 71.77 151 130.4 354 - -
Change - -69.05% 63.28% 110.34% -13.65% 171.53% - -
Enterprise Value (EV) 1 142 43.96 36.84 120.4 108.9 339 343.7 354
Change - -69.05% -16.19% 226.78% -9.5% 211.13% 1.4% 2.98%
P/E -3.19x -1.41x -2.5x -3.63x -3.36x -9.65x -10.7x -47.7x
PBR - - 2.55x 6.18x 6.41x 17.2x 31.6x -
PEG - 0x 0.2x -0.2x 0.1x 0.5x 1.1x 0.6x
Capitalization / Revenue 1,803x - - - - - 360x 6.71x
EV / Revenue 1,803x - - - - - 349x 6.71x
EV / EBITDA -4.74x -1.07x -1.25x -3x -3.18x -13.2x -21.6x -17.2x
EV / EBIT -3.67x -1.06x -1.24x -2.99x -3.17x -9.25x -9.89x -56.3x
EV / FCF -6.03x - -1.46x -4.8x -4.56x -9.92x -12.5x -5.47x
FCF Yield -16.6% - -68.5% -20.8% -21.9% -10.1% -7.97% -18.3%
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -0.73 -0.49 -0.44 -0.51 -0.39 -0.314 -0.2834 -0.0635
Distribution rate - - - - - - - -
Net sales 1 0.0788 - - - - - 0.9842 52.75
EBITDA 1 -29.95 -41.12 -29.54 -40.11 -34.21 -25.72 -15.88 -20.62
EBIT 1 -38.66 -41.34 -29.79 -40.28 -34.32 -36.66 -34.76 -6.288
Net income 1 -31.64 -30.93 -28.13 -36.68 -33.82 -36.31 -36.46 -15.29
Net Debt 1 - - -34.93 -30.58 -21.42 -15.01 -10.26 -
Reference price 2 2.330 0.690 1.100 1.850 1.310 3.030 3.030 3.030
Nbr of stocks (in thousands) 60,954 63,703 65,247 81,603 99,514 1,16,823 - -
Announcement Date 23/03/22 28/03/23 01/04/24 31/03/25 31/03/26 - - -
1CAD in Million2CAD
Estimates

P/E, Detailed evolution



P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
-8.76x - -11.91x - 23Cr
33.86x6.04x17.97x0.95% 4.98TCr
-21.01x245.16x-22.36x-.--% 4.41TCr
33.64x3.26x14.08x-.--% 4.3TCr
47.1x5.45x29.8x-.--% 4.09TCr
28.69x8.67x21.92x0.4% 3.31TCr
33.78x5.53x25.14x-.--% 1.66TCr
24.18x2.1x9.1x1.11% 1.46TCr
77.11x4.06x15.74x-.--% 1.38TCr
Average 27.62x 35.03x 11.05x 0.31% 2.85TCr
Weighted average by Cap. 27.55x 46.64x 12.59x 0.3%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. CRDL Stock
  4. Valuation Cardiol Therapeutics Inc.